KRAS and colorectal carcinoma: In 2009 the PRIME trial (Panitumumab randomized trial in combination with chemotherapy for metastatic CRC to determine efficacy) was first to test KRAS exon 2 mutational status prospectively as a predictive biomarker for mCRC (30).